Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry

INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4....

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, Nobuya, Ueki, Kohjiro, Tanizawa, Yukio, Watada, Hirotaka, Nakamura, Jiro, Yamada, Yuichiro, Shimomura, Iichiro, Nishimura, Rimei, Yamazaki, Tsutomu, Kadowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166248/
https://www.ncbi.nlm.nih.gov/pubmed/25227623
http://dx.doi.org/10.1136/bmjopen-2013-004760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166248/
https://www.ncbi.nlm.nih.gov/pubmed/25227623
http://dx.doi.org/10.1136/bmjopen-2013-004760

Ejemplares similares